CN1317287C - Oligose polysulfate and preparation process thereof - Google Patents
Oligose polysulfate and preparation process thereof Download PDFInfo
- Publication number
- CN1317287C CN1317287C CNB031121799A CN03112179A CN1317287C CN 1317287 C CN1317287 C CN 1317287C CN B031121799 A CNB031121799 A CN B031121799A CN 03112179 A CN03112179 A CN 03112179A CN 1317287 C CN1317287 C CN 1317287C
- Authority
- CN
- China
- Prior art keywords
- product
- heparin
- drying
- dalton
- oligose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The present invention belongs to the technical field of biological medicine, particularly relates to oligose polysulfate and a preparation method thereof. Average molecular weight of the oligose polysulfate prepared by the method is about 3000 dalton, the range of the molecular weight distribution is between 1000 and 5500 dalton, a sulfation degree in the molecules is high, the specific value of sulfate radicals to carboxylate radicals is from 3 to 5, and the anticoagulation titer is smaller than 30 IU/mg. In preparation method of the oligose polysulfate, hydrazinolysis is adopted to eliminate acetyl of heparin, and the heparin is sulfonated after chemically degraded. The compound has the strong functions of inflammatory resistance and asthma resistance, and has the advantages of low anticoagulation titer, no side effect of haemorrhage, etc.
Description
Technical field
The invention belongs to biomedicine field, particularly relate to a kind of many sulfated oligosaccharides for the treatment of asthma and preparation method thereof.
Background technology
By to the pathogenetic research of asthma, having established anti-inflammatory treatment in the world is the primary principle of reatment of bronchial asthma.The anti-asthmatic medicament of using has bronchodilator and hormones anti-inflammatory drug at present, and the former can only play the effect of relief of symptoms, and the hormones anti-inflammatory drug can only use when emergent owing to having bigger side effect.In recent years existing have the report of anti-inflammatory and immunoregulation effect about glycosaminoglycan such as heparin, and have the anapnotherapy of LDH to be used for the research of anti-asthma disease.People such as Ahmed have once reported at United States Patent (USP) " methods of treatment of asthma " (patent No. US 5690910) and have used the treatment by Low molecule heparin asthma.Although heparin has the effect of potential treatment asthma, but it is very difficult that heparin is used for conventional treatment, because its effective dosage ranges is narrow, the composition heterogeneity, have stronger anticoagulating active and cause shortcomings such as hemorrhage, thereby limited its application in this respect.
Summary of the invention
The objective of the invention is to overcome the deficiency of above existing anti-asthmatic medicament, adopt chemical method that heparin is carried out structural modification, provide that a kind of to have an anti-asthma active strong but do not have many sulfated oligosaccharides of hemorrhage side effect and preparation method thereof simultaneously again.
The present invention realizes by following approach:
A kind of many sulfated oligosaccharides contain iduronic acid derivative, glucal acid derivative and glucosamine derivative in the molecule, its chemical structure is as shown below.
Above-mentioned many sulfated oligosaccharides is characterized in that: molecular-weight average is 3000 dalton, and between range of molecular weight distributions 1000～5500 dalton, anticoagulant efficiency＜30IU/mg, the ratio of sulfate radical and carboxylate radical are 3～5.
The method for preparing many sulfated oligosaccharides is characterized in that may further comprise the steps:
(1) heparin is deacetylated: it is 1%～10% solution that heparin is made into concentration; used deacetylated reagent has anhydrous hydrazine, to hydrazino-benzoic acid, hydrazine dihydrochloride, hydrazine hydrate, hydrazonium sulfate and composition thereof etc.; 90～110 ℃ of hydrazinolysis temperature, the time is 3～6 hours.Water-soluble again after the freeze-drying, ethanol sedimentation;
(2) degraded: the throw out of step (1) is made into the aqueous solution by 1%～10% concentration, and the Sodium Nitrite of adding 0.1%～0.5% reacted 1～3 hour in pH1.5～4, the ethanol sedimentation with 80%, vacuum-drying;
(3) degraded product reduction: the product of step (2) is made into the aqueous solution by 10% concentration, the sodium borohydride reduction degraded product with 0.1%～1%, 10～20 hours reaction times, the ethanol sedimentation with 80%, vacuum-drying;
(4) poly-sulfated: that the product of step (3) is dissolved in the methane amide or dimethyl formamide of 6 times of amounts, the chlorsulfonic acid that adds 1～2 times of amount of oligosaccharides amount, chlorsulfonic acid includes 5%～10% the vitriol oil, reacts below 50 ℃ 2～8 hours, with the ethanol termination reaction of 2～6 times of amounts;
(5) sulfonated products purifying: sulfonated products is after reduction, and gel permeation chromatography separates required fragment, and used gel is Sephadex G 50～100, and Superdex 30～200, collect needed component, and freeze-drying gets product.
Many sulfated oligosaccharides that the present invention makes have stronger anti-inflammatory, anti-asthma effect, and it is low to have an anticoagulant efficiency, advantages such as no hemorrhage side effect.
Embodiment
Provide a most preferred embodiment of the present invention below.
Many sulfated oligosaccharides are with heparin deacetylated back degraded, carry out the product of poly-sulfated gained then.Concrete implementation step is as follows:
(1) heparin is deacetylated: taking heparin 10g, be dissolved in the mixture of 100ml anhydrous hydrazine-hydrazonium sulfate (99: 1), and be warming up to 95～100 ℃, reacted 5～6 hours, after the cooling, freeze-drying, water-soluble by 10% concentration again, 70% ethanol sedimentation;
(2) degraded: the ethanol sedimentation thing of step (1) is water-soluble by 10% concentration, transfer pH2～3.5, add 0.3% Sodium Nitrite room temperature reaction 2 hours, transfer pH to 7.0, ethanol sedimentation with 80%;
(3) degraded product reduction: the ethanol sedimentation thing of step (2) is made into 10% aqueous solution, and pH to 7.0 is transferred in the sodium borohydride reduction reaction of adding 0.1% 15 hours, the ethanol sedimentation with 80%, and vacuum-drying gets product 6.3g;
(4) poly-sulfated: the product 6g that gets step (3) is dissolved in the 36ml methane amide, adds 6ml chlorsulfonic acid (including 5% the vitriol oil), and 50 ℃ were reacted 8 hours, with the ethanol sedimentation of 4 times of amounts, vacuum-drying, gets product 7.3g;
(5) sulfonated products purifying: the product 4g that gets step (4) is dissolved in the 10ml water, and last Sephadex G75 post (120 * 3.5cm), with the sodium-chlor wash-out of 0.2mol/L, collect needed component, freeze-drying gets product 2.3g.
Many sulfated oligosaccharides of above-mentioned gained are carried out molecular weight determination, structure determination and anticoagulant efficiency mensuration respectively, obtain a kind of many sulfated oligosaccharides, contain iduronic acid derivative, glucal acid derivative and glucosamine derivative in the molecule, chemical structure is as shown below.
The molecular-weight average of these many sulfated oligosaccharides is 3000 dalton, and between range of molecular weight distributions 1000～5500 dalton, anticoagulant efficiency＜30IU/mg, the ratio of sulfate radical and carboxylate radical are 3～5.
Claims (3)
1. sulfated oligosaccharide more than a kind contains iduronic acid derivative, glucal acid derivative and glucosamine derivative in the molecule, and its chemical structure is as shown below,
X=SO
3 -Or H, n=1～8.
2. according to the described many sulfated oligosaccharides of claim 1, it is characterized in that: molecular-weight average is 3000 dalton, and between range of molecular weight distributions 1000～5500 dalton, anticoagulant efficiency＜30IU/mg, the ratio of sulfate radical and carboxylate radical are 3～5.
3. method for preparing claim 1 or 2 described many sulfated oligosaccharides is characterized in that may further comprise the steps:
(1) heparin is deacetylated: it is 1%～10% solution that heparin is made into concentration, used deacetylated reagent has anhydrous hydrazine, to hydrazino-benzoic acid, hydrazine dihydrochloride, hydrazine hydrate, hydrazonium sulfate and composition thereof, 90～110 ℃ of hydrazinolysis temperature, time is 3～6 hours, water-soluble again after the freeze-drying, ethanol sedimentation;
(2) degraded: the throw out of step (1) is made into the aqueous solution by 1%～10% concentration, and the Sodium Nitrite of adding 0.1%～0.5% reacted 1～3 hour in pH1.5～4, the ethanol sedimentation with 80%, vacuum-drying;
(3) degraded product reduction: the product of step (2) is made into the aqueous solution by 10% concentration, the sodium borohydride reduction degraded product with 0.1%～1%, 10～20 hours reaction times, the ethanol sedimentation with 80%, vacuum-drying;
(4) poly-sulfated: that the product of step (3) is dissolved in the methane amide or dimethyl formamide of 6 times of amounts, the chlorsulfonic acid that adds 1～2 times of amount of oligosaccharides amount, chlorsulfonic acid includes 5%～10% the vitriol oil, reacts below 50 ℃ 2～8 hours, with the ethanol termination reaction of 2～6 times of amounts;
(5) sulfonated products purifying: sulfonated products is after reduction, and gel permeation chromatography separates required fragment, and freeze-drying gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031121799A CN1317287C (en) | 2003-04-18 | 2003-04-18 | Oligose polysulfate and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031121799A CN1317287C (en) | 2003-04-18 | 2003-04-18 | Oligose polysulfate and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1450076A CN1450076A (en) | 2003-10-22 |
| CN1317287C true CN1317287C (en) | 2007-05-23 |
Family
ID=28683990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031121799A Expired - Fee Related CN1317287C (en) | 2003-04-18 | 2003-04-18 | Oligose polysulfate and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1317287C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214591B (en) * | 2013-04-12 | 2015-11-04 | 中国科学院昆明植物研究所 | A kind of lower molecular weight osamine polysaccharid derivative of the talose or derivatives thereof that dewaters containing end 2,5- |
| CN107727762A (en) * | 2017-09-28 | 2018-02-23 | 山东大学 | A kind of method of nitrous acid degradation analysis LMWHs disaccharides structure |
| CN108752500A (en) * | 2018-07-03 | 2018-11-06 | 江南大学 | A method of preparing curdlan sulfuric ester |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084999A1 (en) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications |
| EP0300099A1 (en) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | New pentasaccharides |
| CN1222524A (en) * | 1997-11-19 | 1999-07-14 | 阿克佐诺贝尔公司 | Carbohydrate derivatives |
-
2003
- 2003-04-18 CN CNB031121799A patent/CN1317287C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084999A1 (en) * | 1982-01-15 | 1983-08-03 | D.R.O.P.I.C. (Société Civile) | Process for the preparation of organic oligosaccharides, corresponding to fragments of natural muco-polysaccharides, oligosaccharides obtained and their biological applications |
| EP0300099A1 (en) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | New pentasaccharides |
| CN1222524A (en) * | 1997-11-19 | 1999-07-14 | 阿克佐诺贝尔公司 | Carbohydrate derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1450076A (en) | 2003-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4916219A (en) | Oligosaccharide heparin fragments as inhibitors of complement cascade | |
| US5039529A (en) | Novel heparin derivatives | |
| US5013724A (en) | Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications | |
| CA1171375A (en) | Oligosaccharides having selective anticoagulation activity | |
| RU2617764C2 (en) | Non-anticoagulant glycosaminoglycans with repeating disaccharide units, and their medical application | |
| CN1162339A (en) | Polysaccharides having high iduronic acid content | |
| JP2006516988A (en) | Pharmaceutical composition comprising an active agent and chitosan for sustained drug release or mucoadhesion | |
| CN103382232B (en) | The preparation of nadroparin calcium and purifying process | |
| ITMI970678A1 (en) | GLYCOSAMINOGLICANS WITH HIGH ANTI-THROMBOTIC ACTIVITY | |
| CN1317287C (en) | Oligose polysulfate and preparation process thereof | |
| JPH08508540A (en) | Non-anticoagulant, chemically modified heparin-like substances for the treatment of hypovolemic shock and related shock syndromes | |
| CN107406525A (en) | The process of sulfating of glycosaminoglycan | |
| CN1789287A (en) | Poly-sulfated chondroitin sulfate and preparation method thereof | |
| CA2489862C (en) | Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation | |
| CN116003645A (en) | Fucoidan, and preparation and purification method thereof | |
| CN100345868C (en) | Dermatan sulfate with low molecule and its preparing method | |
| CN104404110A (en) | Preparation method for hyaluronic acid derivative with high anticoagulant activity | |
| CN1286853C (en) | Figwort polysaccharide and its production process and use | |
| CN104610459A (en) | Low molecular weight imitated stichopus japonicus selenka glycosaminoglycans, preparation method, and applications thereof | |
| CN112500504B (en) | Tumor targeting fucosan sulfate and preparation method thereof | |
| CN112521431B (en) | Anticoagulation fucoidan oligosaccharide and preparation method thereof | |
| WO2002076475A2 (en) | Glycosaminoglycan anticoagulants derived from fish | |
| TWI854990B (en) | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions | |
| RU2333222C2 (en) | Epimerised k5 polysaccharide derivatives with high sulfation degree | |
| Saravanan et al. | Partial sequencing, structural characterization, and anticoagulant activity of heparan sulfate and sulfated chitosan from selected Indian marine mollusks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070523 Termination date: 20100418 |